Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Stanxime

Approved

STANDARD

Stanxime

Shin Poong Pharmaceutical Co., Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: a1a2a5f97a20af47
Company: Shin Poong Pharmaceutical Co., Ltd.
Type: Standard

Approval Details

Approval Id: a1a2a5f97a20af47
Drug Approval Philippines Name: Stanxime
Product Name: Stanxime
Registration Number: DRP-3036-02
Brand Name: Stanxime
Generic Name: Cefuroxime (As Sodium)
Dosage Form: Powder For Injection (IM/IV)
Dosage Strength: 750mg
Manufacturer: Shin Poong Pharmaceutical Co., Ltd.
Importer: Phil Shinpoong Pharma, Inc.
Distributor: Better Option Pharmaceuticals, Inc.
Issuance Date: 25 June 2021
Expiry Date: 11 April 2026
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

a1a2a5f97a20af47

Type

Standard

Back to Philippines FDA Approvals

Stanxime - Philippines FDA Drug Approval Details